A prospective phase II study on dose escalation using PET based adaptive IMRT stage II-III non small lung cancer

• Conditions: Stage II-III Non small lung cancer; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2011-003124-12-BE
• Lead Sponsor: Cliniques Universitaires Saint Luc

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-09-24
• Last Update Posted: 7 October 2014

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

•Histologically proven NSCLC
•Non resectable stage III or medically inoperable stage II disease when a stereotactic treatment cannot be proposed
•No contraindication for induction or concomitant chemotherapy
•No prior thoracic radiation
•Moderate-to-good lung function with :
oFEV1/DLCO = 30% of the predicted value
oFEV1 = 1L

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 20

Exclusion Criteria

None

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified